EV/EBITDA
Enterprise Value to EBITDA

13.9
Current
13.4
Median
13
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
13.9
=
Enterprise Value
384.5m EUR
/
EBITDA
44.7m CAD
All Countries
Close
Market Cap EV/EBITDA
CA
SNDL Inc
F:VY4
461.3m EUR 13.9
US
Eli Lilly and Co
NYSE:LLY
985.4B USD 35.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
506.1B USD 16.5
CH
Roche Holding AG
SIX:ROG
252.7B CHF 11.5
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP 107.9
CH
Novartis AG
SIX:NOVN
206.9B CHF 11.5
US
Merck & Co Inc
NYSE:MRK
246.7B USD 9.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 9.1
IE
Endo International PLC
LSE:0Y5F
209B USD 331.1
US
Pfizer Inc
NYSE:PFE
142.4B USD 7.4
EBITDA Growth EV/EBITDA to Growth
CA
SNDL Inc
F:VY4
Average EV/EBITDA: 400
13.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
107.9
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
hidden
2-Years Forward
EV/EBITDA
hidden
3-Years Forward
EV/EBITDA
N/A